Literature DB >> 11728275

Therapeutic angiogenesis: a new treatment modality for ischemic heart disease.

M A Nelson1, J Passeri, W H Frishman.   

Abstract

Angiogenesis is the process of new blood vessel formation, and has potential clinical use in the management of ischemic heart disease. A considerable amount of ongoing research has recently focused on the process of angiogenesis, including the identification of various factors that can inhibit or stimulate this process. The picture that is emerging suggests that a complex set of interactions involving various cells and cellular products is the key to angiogenesis. In particular, endothelial cells and growth factors, such as vascular endothelial growth factor and fibroblast growth factor, appear to play integral roles in angiogenesis. Various preclinical studies involving animal models of ischemia explored the potential use of angiogenesis in ischemic disease. Based on encouraging results, a number of clinical trials involving angiogenesis have been initiated to determine whether the process of angiogenesis also offers therapeutic benefit in humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11728275

Source DB:  PubMed          Journal:  Heart Dis        ISSN: 1521-737X


  4 in total

1.  Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Int J Cardiol       Date:  2010-08-02       Impact factor: 4.164

2.  Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Microvasc Res       Date:  2010-04-01       Impact factor: 3.514

3.  Enhancing engineered vascular networks in vitro and in vivo: The effects of IGF1 on vascular development and durability.

Authors:  Claudia C Friedrich; Yunfeng Lin; Alexander Krannich; Yinan Wu; Joseph P Vacanti; Craig M Neville
Journal:  Cell Prolif       Date:  2017-11-07       Impact factor: 6.831

4.  Genetic variants of VEGFR-1 gene promoter in acute myocardial infarction.

Authors:  Haihua Wang; Shufang Zhang; Na Wang; Jie Zhang; Mingkai Chen; Xiaohui He; Yinghua Cui; Shuchao Pang; Bo Yan
Journal:  Hum Genomics       Date:  2019-11-19       Impact factor: 4.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.